Novo Nordisk sales beat estimates, but the story wasn’t Ozempic - MarketWatch
1. Novo Nordisk's profit rose 29% to 28.23 billion kroner. 2. Sales grew 30% to 85.68 billion kroner, exceeding analyst expectations. 3. Insulin sales drove growth, offsetting expectations for weight-loss drug sales. 4. Novo Nordisk targets 16-24% sales growth for 2025 amid investor uncertainty. 5. Regulatory filings for next-gen weight-loss drugs are expected soon.